Latest News by Industry
SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution.
“We are pleased to welcome Marc, Glenn, Lisa, John, and Michael to the Myriad team. They are all accomplished leaders who will each play an instrumental role in accelerating the growth of our commercial business forward and elevating our products to their full potential,” said Paul J. Diaz, president and CEO, Myriad Genetics. “Their combined depth of experience in healthcare and respective areas of expertise will continue to enrich our strong foundation for long-term sustainable growth, profitability and innovation.”
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to elevating the company’s product portfolio, customer-centric commercial capabilities and sales and marketing execution, accelerating the growth of the company’s commercial business, the company’s strong foundation for long-term sustainable growth, profitability and innovation, and Oberg and Lyons joining the company effective January 3, 2023. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
| Media Contact: Glenn Farrell (801) 505-5195 Glenn.Farrell@myriad.com | Investor Contact: Matt Scalo (801) 584-3532 Matt.Scalo@myriad.com | |